Specifics of the deal have not been disclosed although it is understood that Daiichi called on Saltigo – a wholly owned subsidiary of German chemicals firm Lanxess – to help it prepare for the commercial launch of the product in question.
Saltigo did not reveal where the Daiichi product would be made, but one possibility is the firm’s manufacturing site in Leverkusen which was accredited by the Japanese Ministry of Health, Labor and Welfare (MHLW) in 2012.
At the time spokesman Andreas Stolle said: “For us, its value is similar to that of a certificate from the US Food and Drug Administration (FDA). It is an essential milestone for further expanding our business activity in Japan and safeguarding it on a sustainable basis."